tirzepatide and cancer BREAKING NEWS 🚨 A new study from the University of Michigan found that SHRINKS BREAST TUMORS IN MICE. For women 40–55, this matters. Weight gain breast cancer risk both 💊 A new drug combo

The case reports suggest that reductions of 15 to 25% from the original levothyroxine dose are common in patients experiencing significant weight loss on GLP-1 agonists

government provides a wealth of resources to help consumers make informed decisions about cosmetic treatments: FDA Consumer Guides: The FDAs Resources for Consumers on Cosmetics page offers tips on safe cosmetic use, understanding product labels, and reporting adverse reactions

Where appropriate, we also draw on harm reduction principles, meeting people where they are rather than demanding immediate perfection in their relationship with food or their body

When Saxenda might still be appropriate Saxenda may be considered if you have not previously tolerated weekly GLP-1 medications, prefer daily dosing (the ability to stop quickly if side effects occur), or cost is a primary concern, and Wegovy or Mounjaro are unaffordable

Red flags for suspiciously cheap retatrutide Not every low price is a red flag